SG Americas Securities’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.63M | Buy |
54,691
+20,591
| +60% | +$616K | ﹤0.01% | 1493 |
|
|
2025
Q4 | $1.3M | Sell |
34,100
-9,850
| -22% | -$320K | ﹤0.01% | 1797 |
|
|
2025
Q3 | $1.05M | Buy |
43,950
+12,024
| +38% | +$226K | ﹤0.01% | 1411 |
|
|
2025
Q2 | $473K | Buy |
+31,926
| New | +$529K | ﹤0.01% | 1716 |
|
|
2024
Q4 | – | Sell |
-29,125
| Closed | -$407K | – | 3635 |
|
|
2024
Q3 | $407K | Buy |
29,125
+12,241
| +73% | +$128K | ﹤0.01% | 1877 |
|
|
2024
Q2 | $139K | Buy |
+16,884
| New | +$114K | ﹤0.01% | 2364 |
|
|
2023
Q4 | – | Sell |
-131,891
| Closed | -$1.18M | – | 3456 |
|
|
2023
Q3 | $1.18M | Buy |
+131,891
| New | +$1.86M | 0.01% | 1139 |
|
|
2023
Q2 | – | Sell |
-69,260
| Closed | -$1.56M | – | 3174 |
|
|
2023
Q1 | $1.56M | Buy |
+69,260
| New | +$1.47M | 0.02% | 822 |
|
|
2022
Q3 | – | Sell |
-33,635
| Closed | -$815K | – | 3569 |
|
|
2022
Q2 | $815K | Buy |
33,635
+9,790
| +41% | +$246K | 0.01% | 1485 |
|
|
2022
Q1 | $614K | Sell |
23,845
-6,799
| -22% | -$181K | ﹤0.01% | 1754 |
|
|
2021
Q4 | $951K | Sell |
30,644
-19,553
| -39% | -$551K | 0.01% | 1692 |
|
|
2021
Q3 | $1.22M | Buy |
50,197
+35,705
| +246% | +$656K | 0.01% | 1732 |
|
|
2021
Q2 | $211K | Sell |
14,492
-9,475
| -40% | -$187K | ﹤0.01% | 2320 |
|
|
2021
Q1 | $598K | Buy |
23,967
+5,652
| +31% | +$156K | ﹤0.01% | 1888 |
|
|
2020
Q4 | $499K | Buy |
18,315
+1,227
| +7% | +$28.6K | ﹤0.01% | 1991 |
|
|
2020
Q3 | $315K | Buy |
17,088
+6,343
| +59% | +$123K | ﹤0.01% | 1909 |
|
|
2020
Q2 | $219K | Buy |
10,745
+2,407
| +29% | +$38.3K | ﹤0.01% | 2789 |
|
|
2020
Q1 | $122K | Buy |
+8,338
| New | +$125K | ﹤0.01% | 2855 |
|
|
2019
Q2 | – | Sell |
-6,328
| Closed | -$143K | – | 3430 |
|
|
2019
Q1 | $143K | Buy |
+6,328
| New | +$140K | ﹤0.01% | 2814 |
|
|
2017
Q4 | – | Sell |
-14,580
| Closed | -$363K | – | 3638 |
|
|
2017
Q3 | $363K | Buy |
14,580
+6,413
| +79% | +$141K | ﹤0.01% | 2081 |
|
|
2017
Q2 | $158K | Buy |
8,167
+146
| +2% | +$2.65K | ﹤0.01% | 2591 |
|
|
2017
Q1 | $148K | Sell |
8,021
-8,408
| -51% | -$164K | ﹤0.01% | 2671 |
|
|
2016
Q4 | $311K | Buy |
+16,429
| New | +$336K | ﹤0.01% | 2012 |
|
|
2015
Q3 | – | Sell |
-4,773
| Closed | -$158K | – | 2690 |
|
|
2015
Q2 | $158K | Sell |
4,773
-3,359
| -41% | -$92K | ﹤0.01% | 2098 |
|
|
2015
Q1 | $195K | Buy |
+8,132
| New | +$124K | ﹤0.01% | 1893 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
SG Americas Securities's TVTX Position: Q1 2026 in Review
SG Americas Securities increased its Travere Therapeutics (TVTX) stake by 60% in Q1 2026, buying an estimated $616K and bringing the position to 54,691 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1493.
SG Americas Securities first reported a position in TVTX in Q1 2015 and has held it in 25 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- SG Americas Securities held 54,691 shares of Travere Therapeutics worth $1.63M as of Q1 2026.
- SG Americas Securities bought 20,591 Travere Therapeutics shares in Q1 2026, an estimated $616K.
- Travere Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1493 holding.
- SG Americas Securities first reported a position in Travere Therapeutics in Q1 2015 and has held it in 25 quarters since.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.